Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Role of the caspase-8/RIPK3 axis in Alzheimer’s disease pathogenesis and Aβ-induced NLRP3 inflammasome activation
Sushanth Kumar, Sakar Budhathoki, Christopher B. Oliveira, August D. Kahle, O. Yipkin Calhan, John R. Lukens, Christopher D. Deppmann
Sushanth Kumar, Sakar Budhathoki, Christopher B. Oliveira, August D. Kahle, O. Yipkin Calhan, John R. Lukens, Christopher D. Deppmann
View: Text | PDF
Research Article Inflammation Neuroscience

Role of the caspase-8/RIPK3 axis in Alzheimer’s disease pathogenesis and Aβ-induced NLRP3 inflammasome activation

  • Text
  • PDF
Abstract

The molecular mediators of cell death and inflammation in Alzheimer’s disease (AD) have yet to be fully elucidated. Caspase-8 is a critical regulator of several cell death and inflammatory pathways; however, its role in AD pathogenesis has not yet been examined in detail. In the absence of caspase-8, mice are embryonic lethal due to excessive receptor interacting protein kinase 3–dependent (RIPK3-dependent) necroptosis. Compound RIPK3 and caspase-8 mutants rescue embryonic lethality, which we leveraged to examine the roles of these pathways in an amyloid β–mediated (Aβ-mediated) mouse model of AD. We found that combined deletion of caspase-8 and RIPK3, but not RIPK3 alone, led to diminished Aβ deposition and microgliosis in the mouse model of AD carrying human presenilin 1 and amyloid precursor protein with 5 familial AD mutations (5xFAD). Despite its well-known role in cell death, caspase-8 did not appear to affect cell loss in the 5xFAD model. In contrast, we found that caspase-8 was a critical regulator of Aβ-driven inflammasome gene expression and IL-1β release. Interestingly, loss of RIPK3 had only a modest effect on disease progression, suggesting that inhibition of necroptosis or RIPK3-mediated cytokine pathways is not critical during midstages of Aβ amyloidosis. These findings suggest that therapeutics targeting caspase-8 may represent a novel strategy to limit Aβ amyloidosis and neuroinflammation in AD.

Authors

Sushanth Kumar, Sakar Budhathoki, Christopher B. Oliveira, August D. Kahle, O. Yipkin Calhan, John R. Lukens, Christopher D. Deppmann

×

Figure 6

Caspase-8 promotes Aβ-induced IL-1β release from mixed astrocyte–microglia cultures.

Options: View larger image (or click on image) Download as PowerPoint
Caspase-8 promotes Aβ-induced IL-1β release from mixed astrocyte–microgl...
(A) Schematic for treatment paradigm. Mixed astrocyte–microglia cultures were primed for 3 hours with 500 ng/mL LPS, then treated for 24 hours with oAβs. Supernatants were then harvested and evaluated for IL-1β release. (B) Supernatants were collected from WT, Ripk3–/–, and DKO mixed glial cultures after 24 hours of treatment with either vehicle, 5 μM, or 10 μM oAβs, and evaluated for IL-1β release via ELISA. 5 μM: WT versus DKO **P = 0.0087, and Ripk3–/– versus DKO *P = 0.0381; 10 μM: WT versus DKO **P = 0.0012, and Ripk3–/– versus DKO ***P = 0.006. (C) WT mixed glial cultures were treated with oAβs either in the presence of an NLRP3 inhibitor (NLRP3i) (MCC950, used at 1 μM), a caspase-1 inhibitor (caspase-1i) (Ac-YVAD-cmk, used at 10 μM), or a caspase-8 inhibitor (caspase-8i) (zIETD-fmk, used at 10 μM). DMSO versus DMSO (+ oAβs), ***P < 0.001; DMSO (+ oAβs) versus NLRP3i, ****P < 0.0001; DMSO (+ oAβs) versus caspase-1i, ***P < 0.001; DMSO (+ oAβs) versus caspase-8i, ****P < 0.0001. (D–G) Mixed-culture gene transcript levels for Nlrp3, Il1b, Casp1, and Pycard before and after 3-hour LPS priming (n = 4 WT mice, n = 4 Ripk3–/– mice, and n = 4 DKO mice). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (B) Data were analyzed by 2-way ANOVA followed by Tukey’s post hoc test. (C–G) Data were analyzed by 1-way ANOVA followed by Tukey’s post hoc test. Data are from at least 3 independent experiments and expressed as mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts